A SWITCH TO BELATACEPT-BASED IMMUNOSUPPRESIVE REGIMEN IN KIDNEY TRANSPLANT RECIPIENTS FROM CALCINEURIN INHIBITORS (CNI) HAS A FAVOURABLE SAFETY PROFILE AND RESULTS IN IMPROVED RENAL FUNCTION: 12-MONTH RESULTS FROM A PHASE II STUDY

被引：0
|
作者：
Walker, R. G. [1 ]
Rostaing, L. [2 ]
Nainan, G. [3 ]
Rial M, Del C. [4 ]
Steinberg, S. [5 ]
Vincenti, F. [6 ]
Shi, R. [7 ]
Di Russo, G. [7 ]
Thomas, D. [7 ]
Xinos, C. [8 ]
Grinyo, J. [9 ]
机构：
[1] Royal Melbourne Hosp, Melbourne, Vic, Australia
[2] Univ Hosp, Toulouse, France
[3] Lakeshore Hosp, Cochin, Kerala, India
[4] Inst Nefrol, Buenos Aires, DF, Argentina
[5] Sharp Mem Hosp & Rehabil Ctr, San Diego, CA USA
[6] UCSF, San Francisco, CA USA
[7] Bristol Myers Squibb, Princeton, NJ USA
[8] Bristol Myers Squibb, Melbourne, Vic, Australia
[9] Univ Hosp Bellvitge, Barcelona, Spain
来源：
IMMUNOLOGY AND CELL BIOLOGY | 2011年 / 89卷 / 07期
关键词：
D O I：
暂无
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
引用
收藏
页码：A3 / A3
页数：1
相关论文
共 50 条
  • [41] Post Hoc Subgroup Analysis of ZEUS: Outcome On Renal Function, Efficacy and Safety in Living-Donor Kidney Transplant Recipients After Conversion From a Calcineurin Inhibitor to an Everolimus Based Regimen
    Lehner, F.
    Sommerer, C.
    Arns, W.
    Reinke, P.
    Eisenberger, U.
    Wuthrich, R.
    Pressmar, K.
    Hauser, I.
    Porstner, M.
    May, C.
    Paulus, E.
    Muehlfeld, A.
    Suwelack, B.
    Wolters, H.
    Witzke, O.
    Stahl, R.
    Budde, K.
    TRANSPLANTATION, 2014, 98 : 613 - 613
  • [42] Post Hoc Subgroup Analysis of ZEUS: Outcome On Renal Function, Efficacy and Safety in Living-Donor Kidney Transplant Recipients After Conversion From a Calcineurin Inhibitor to an Everolimus Based Regimen
    Lehner, F.
    Sommerer, C.
    Arns, W.
    Reinke, P.
    Eisenberger, U.
    Wuthrich, R.
    Pressmar, K.
    Hauser, I.
    Porstner, M.
    May, C.
    Paulus, E.
    Muehlfeld, A.
    Suwelack, B.
    Wolters, H.
    Witzke, O.
    Stahl, R.
    Budde, K.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 : 613 - 613
  • [43] Efficacy, safety and renal function outcomes with early conversion to everolimus with reduced tacrolimus and steroid elimination in pediatric kidney transplant recipients: Results from the cradle study
    Toenshoff, Burkhard
    Tedesco, Helio
    Ettenger, Robert
    Bjerre, Anna
    Christian, Martin
    Dello Strologo, Luca
    Marks, Stephen
    Pape, Lars
    Lopez, Patricia
    Cousin, Marc
    Pandey, Priti
    Rauer, Barbara
    Meier, Matthias
    PEDIATRIC TRANSPLANTATION, 2019, 23
  • [44] Early Conversion to Everolimus in <i>De Novo</i> Kidney Transplant Recipients: 12-Month Results from the ELEVATE Study
    de Fijter, J.
    Holdaas, H.
    Speziale, A.
    Junge, G.
    Wang, Z.
    Cruzado, J.
    van der Giet, M.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2015, 15
  • [45] Renal Function Outcomes in De Novo Kidney Transplant Recipients Receiving Everolimus with Reduced-Exposure Calcineurin Inhibitor versus Mycophenolate with Standard-Exposure Calcineurin Inhibitor: Results from the TRANSFORM Study
    Oppenheimer, Federico
    Russ, Graeme
    Viklicky, Ondrej
    Oberbauer, Rainer
    Garcia, Valter
    Witzke, Oliver
    Kuypers, Dirk
    Danguilan, Romina
    Das Gupta, Ayan
    Bernhardt, Peter
    Sommerer, Claudia
    TRANSPLANTATION, 2018, 102 : S363 - S363
  • [46] Effect of Everolimus on Cardiovascular Parameters in <i>De Novo</i> Kidney Transplant Recipients: 12-Month Results from the ELEVATE Study
    Holdaas, H.
    van der Giet, M.
    de Fijter, J.
    Speziale, A.
    Escrig, C.
    Junge, G.
    Wang, Z.
    Cruzado, J.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2015, 15
  • [47] Effect of Early Attainment of Everolimus Target Trough Levels on Efficacy-Safety Outcomes in De Novo Kidney Transplant Recipients: 12-Month Results from US92 and TRANSFORM Studies.
    Shihab, F.
    Qazi, Y.
    Peddi, V.
    Shaffer, D.
    Kim, D.
    McCague, K.
    Patel, D.
    Mulgaonkar, S.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 259 - 259
  • [48] Effect of Everolimus on Left Ventricular Hypertrophy in <i> De Novo</i> Kidney Transplant Recipients: 12-Month Results from the ELEVATE Study
    van der Giet, M.
    Holdaas, H.
    de Fijter, J.
    Speziale, A.
    Escrig, C.
    Junge, G.
    Wang, Z.
    Cruzado, J.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2015, 15
  • [49] Post Hoc Subgroup Analysis of ZEUS: Outcome on Renal Function, Efficacy and Safety in Living-Donor Kidney Transplant Recipients After Conversion from a Calcineurin Inhibitor to an Everolimus Based Regimen: 5 Year Follow-Up Data
    Lehner, F.
    Budde, K.
    Wuethrich, R.
    Reinke, P.
    Arns, W.
    Muehlfeld, A.
    Eisenberger, U.
    Stahl, R.
    Heller, K.
    Witzke, O.
    Suwelack, B.
    Wolters, H.
    Hauser, I.
    Porstner, M.
    Sommerer, C.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2015, 15
  • [50] POST HOC SUBGROUP ANALYSIS OF ZEUS: OUTCOME ON RENAL FUNCTION, EFFICACY AND SAFETY IN LIVING-DONOR KIDNEY TRANSPLANT RECIPIENTS AFTER CONVERSION FROM A CALCINEURIN INHIBITOR TO AN EVEROLIMUS BASED REGIMEN: 5 YEAR FOLLOW-UP DATA
    Lehner, F.
    Budde, K.
    Suwelack, B.
    Arns, W.
    Wuethrich, R. P.
    Reinke, P.
    Muehlfeld, A.
    Eisenberger, U.
    Stahl, R.
    Porstner, M.
    Heller, K.
    Wolters, H. H.
    Witzke, O.
    Hauser, I. A.
    Sommerer, C.
    TRANSPLANT INTERNATIONAL, 2015, 28 : 58 - 58
12345